Attana AB

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0010547273
SEK
0.01
-0.02 (-64.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.05

stock-summary
Return on Equity

-57.71%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
80.0%
0%
80.0%
6 Months
-55.0%
0%
-55.0%
1 Year
-80.52%
0%
-80.52%
2 Years
-88.58%
0%
-88.58%
3 Years
-97.73%
0%
-97.73%
4 Years
-99.07%
0%
-99.07%
5 Years
-98.37%
0%
-98.37%

Attana AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-2.80%
EBIT Growth (5y)
3.25%
EBIT to Interest (avg)
-9.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.20
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
-0.00
EV to EBITDA
EV to Capital Employed
0.00
EV to Sales
0.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-42.13%
ROE (Latest)
-52.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 171.43% vs -30.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -2.50% vs -17.65% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.90",
          "val2": "0.70",
          "chgp": "171.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.90",
          "val2": "-2.60",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.10",
          "val2": "-4.00",
          "chgp": "-2.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,068.40%",
          "val2": "-5,805.30%",
          "chgp": "373.69%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -19.61% vs -32.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.25% vs 5.48% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.10",
          "val2": "5.10",
          "chgp": "-19.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.90",
          "val2": "-11.40",
          "chgp": "30.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.80",
          "val2": "1.40",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.80",
          "val2": "-13.80",
          "chgp": "7.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,987.40%",
          "val2": "-2,406.80%",
          "chgp": "41.94%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.90
0.70
171.43%
Operating Profit (PBDIT) excl Other Income
-3.90
-2.60
-50.00%
Interest
0.00
0.70
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.10
-4.00
-2.50%
Operating Profit Margin (Excl OI)
-2,068.40%
-5,805.30%
373.69%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 171.43% vs -30.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -2.50% vs -17.65% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4.10
5.10
-19.61%
Operating Profit (PBDIT) excl Other Income
-7.90
-11.40
30.70%
Interest
2.80
1.40
100.00%
Exceptional Items
-1.60
0.00
Consolidate Net Profit
-12.80
-13.80
7.25%
Operating Profit Margin (Excl OI)
-1,987.40%
-2,406.80%
41.94%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -19.61% vs -32.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.25% vs 5.48% in Dec 2023

stock-summaryCompany CV
About Attana AB stock-summary
stock-summary
Attana AB
Pharmaceuticals & Biotechnology
Attana AB is a Sweden-based biotechnology company specializing in in vitro characterization of molecular interactions mimicking in vivo conditions. The Company develops proprietary label-free biosensors, based on the Quartz Crystal Microbalance (QCM) technology, for biochemical, crude, sera and cell-based assays. Its products and research services are used by pharmaceutical and biotechnology companies to quality control the production line of a biological pharmaceutical or gain insight into advanced dynamic features of target molecules, as well as by academic institutions within the life sciences. Attana’s biosensors are used to determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
Company Coordinates stock-summary
Company Details
Greta Arwidssons v. 21 , STOCKHOLM None : 114 19
stock-summary
Tel: 46 8 41020000
stock-summary
Registrar Details